17 December 2021 - EMA has recommended granting a marketing authorisation in the EU for Oxbryta (voxelotor) for the treatment of haemolytic anaemia due to sickle cell disease in patients 12 years of age and older.

Oxbryta is to be used on its own or in combination with hydroxycarbamide (also known as hydroxyurea).

Read EMA press release